// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

A TEG-guided treatment algorithm for major surgical bleeding

S. Dawson - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

A Tertiary Centre Experience of Late Amniocentesis in Obstetric Management of Women with Inherited Bleeding Disorders

B. Madan - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

N/A

ADAMTS13 activity and non-parallel vWF Ristocetin CoFactor activity are associated with severity of COVID-19 infection

S. MacDonald - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

folitixorin calcium

Age and sex distribution of the prevalence and incidence of hospitalisations and mortality due to bleeding in England 2014-2019

K. Creeper - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

An Integrated Clinical and Pathological Approach to Rare Bleeding Disorders

R. Hargreaves - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Analysis of TFPI-protein S anticoagulant function in vivo.

A. Petri - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

folitixorin calcium

Analysis of uncharacterised Von Willebrand’s Disease causing mutations located in the D4 and C-domains: identification of a novel type 2A variant and gain-of-function VWF

G. Mobayen - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Angiopoietin-2 binds to Von Willebrand Factor within Endothelial Cells and after Release from Weibel Palade Bodies and mediates Von Willebrand Factor dependent angiogenesis

T. McKinnon - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

L-Tyrosine

Annualized Bleed Rates in Severe Hemophilia A After Switch to Emicizumab Based on CHESS II Data, Including an Oversample of Emicizumab Patients

M. Mancuso - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

FVIII

Anti-PF4 IgG levels in patients with VITT remain high at 7 months following vaccination and can still activate platelets

S. Montague - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Anti-Thrombotic Effects of the Proteasome Inhibitor Carfilzomib on the Endothelium

A. Hjazi - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

carfilzomib Intravenous

Anti-Xa and APTT stability in whole blood – a comparison of UFH & LMWH

P. Gajendra - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Heparin

Antibody-mediated depletion of human CLEC-2 in a novel humanized mouse model

H. Brown - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Antiphospholipid antibodies in patients with acute ischaemic stroke during the COVID-19 pandemic

P. Mittal - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Coronavirus disease

N/A

Apixaban for venous thromboembolism treatment in obese patients with weight >120kg or BMI >40 kg m2

T. Groves - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

apixaban

Assay of the factor VIIIa mimetic, Mim8, using one-stage clotting assay requires a product-specific reference material

H. Wilmot - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

FVIII

Assessing Endothelial Activation and Risk of Bleeding in patients receiving VV-ECMO supportive therapy for COVID-19 using non-standard laboratory assays

T. Edwards - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

Fibrinogen (IV)

Association of polygenic risk scores for severe mental illness with risk of venous thromboembolism

R. Strawbridge - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Audit of the use of Fibclot (Fibrinogen concentrate) in patients without congenital afibrinogenaemia

M. Ul-haq - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Fibrinogen (IV)

Automated genotyped matching of platelets to prevent alloimmunisation

N. Gleadall - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved